Sarah Cooley - Fate Therapeutics Senior Vice President - Clinical Translation
| FATE Stock | USD 0.94 0.03 3.30% |
President
Dr. Sarah Cooley, M.D., M.S., is Senior Vice President Clinical Translation of the Company. She a leading expert in the field of natural killer cell receptor immunogenetics and in the clinical development of NK cell cancer immunotherapies, has joined the Company as Senior Vice President, Clinical Translation. Dr. Cooley brings to Fate Therapeutics more than 12 years of leadership in the field of NK cell clinical research and development, having most recently served as Associate Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota. Dr. Cooley will be responsible for leading translational medicine across the Company cellbased cancer immunotherapy programs and for early clinical development of certain of the Company NK cell product candidates. At the University of Minnesota Masonic Cancer Center, Dr. Cooley played a critical role in the development of translational research infrastructure, serving as the Medical Director for the Clinical Trials Office, for the Oncology Informatics Shared Resource and most recently as the Director of Investigator Initiated Research and of the Cancer Research Translational Initiative. Throughout her career, Dr. Cooley led 15 clinical trials of NK cell or immunotherapybased cancer treatments since 2019.
| Tenure | 6 years |
| Phone | 858 875 1800 |
| Web | https://www.fatetherapeutics.com |
Fate Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2581) % which means that it has lost $0.2581 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5421) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | PRESIDENT Age | ||
| Edward III | Intellia Therapeutics | 48 | |
| Andrew JD | Verve Therapeutics | 58 | |
| Christopher Murray | Blueprint Medicines Corp | 61 | |
| Fouad MD | Blueprint Medicines Corp | 56 | |
| Juan Jaen | Arcus Biosciences | 67 | |
| Joseph Newell | Atara Biotherapeutics | 54 | |
| Hyam MD | Century Therapeutics | 66 | |
| Laura SeppLorenzino | Intellia Therapeutics | 63 | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.26 |
Fate Therapeutics Leadership Team
Elected by the shareholders, the Fate Therapeutics' board of directors comprises two types of representatives: Fate Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fate. The board's role is to monitor Fate Therapeutics' management team and ensure that shareholders' interests are well served. Fate Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fate Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Hickingbottom, Senior Development | ||
| Tunde Babalola, Senior Operations | ||
| Andrew Henry, Senior Operations | ||
| Jessica Francis, Vice Operations | ||
| YuWaye MD, Chief Officer | ||
| Cindy Tahl, General Secretary | ||
| Edward III, Chief Officer | ||
| Victor Hong, Vice Finance | ||
| Bahram Valamehr, Chief Development Officer | ||
| Bahram MBA, President Development | ||
| Scott Wolchko, Founder, CEO and President and Director | ||
| Jim MBA, Senior Development | ||
| MS MBA, Chief Officer | ||
| Cindy JD, Corporate Counsel | ||
| Yu Cai, Head Counsel | ||
| Jerome Bressi, Senior Quality | ||
| Mark DVM, Chief Officer | ||
| Sarah Cooley, Senior Vice President - Clinical Translation |
Fate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fate Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (25.27) % | ||||
| Current Valuation | (88.31 M) | ||||
| Shares Outstanding | 114.6 M | ||||
| Shares Owned By Insiders | 2.26 % | ||||
| Shares Owned By Institutions | 89.80 % | ||||
| Number Of Shares Shorted | 13.06 M | ||||
| Price To Earning | (4.35) X | ||||
| Price To Book | 0.33 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.